# Amrit Nagpal

Amrit Nagpal is a managing director of Redmile Group, LLC, a healthcare-focused investment firm based in San Francisco and New York, where he works on private life-sciences investments; SEC filings name him in connection with Redmile Biopharma Investments II, L.P., a Redmile investment vehicle.<sup>[1](https://www.sec.gov/Archives/edgar/data/1672688/000110465921094585/0001104659-21-094585.txt)</sup><sup> • </sup><sup>[2](https://theorg.com/org/evox-therapeutics/org-chart/amrit-nagpal)</sup> He is best documented as Redmile's representative on the board of Absci Corporation, a position he has held since 2021.

| Key fact | Detail |
|---|---|
| Current role | Managing Director, Private Investments, Redmile Group, LLC<sup>[2](https://theorg.com/org/evox-therapeutics/org-chart/amrit-nagpal)</sup> |
| Filing capacity | Named in SEC filings alongside Redmile Biopharma Investments II, L.P.<sup>[1](https://www.sec.gov/Archives/edgar/data/1672688/000110465921094585/0001104659-21-094585.txt)</sup> |
| Board seat | Absci Corporation, as Redmile's representative since 2021<sup>[1](https://www.sec.gov/Archives/edgar/data/1672688/000110465921094585/0001104659-21-094585.txt)</sup> |

## Role and fund structure: what filings show

An Absci Corporation Section 16 filing from 2021 describes the structure that links Nagpal to the [Redmile Biopharma Investments](https://www.edgepedia.org/redmile-biopharma-investments) vehicle. Redmile Biopharma Investments II, L.P. directly owned Absci's convertible preferred stock, which entitled the holder to appoint one director. Because of that appointment right, Redmile Group, Redmile principal [Jeremy Green](https://www.edgepedia.org/jeremy-green), the partnership, and Nagpal himself were each treated as directors by deputization under Section 16 of the [Securities Exchange Act of 1934](https://www.edgepedia.org/securities-exchange-act-of-1934), making them subject to the insider reporting and short-swing profit rules that apply to directors.<sup>[1](https://www.sec.gov/Archives/edgar/data/1672688/000110465921094585/0001104659-21-094585.txt)</sup>

The distinction between being a general partner and being named in filings matters here. The public record retrieved for this article identifies Nagpal as a Redmile managing director and board representative; it does not document him in the formal capacity of a member of the general partner entity of the issuer vehicle, so the exact legal role within the Redmile Biopharma Investments structure rests on the roster description rather than on a verified filing excerpt.

## Board seats

Nagpal was elected to the board of Absci Corporation as Redmile's representative, in connection with the preferred stock position held by Redmile Biopharma Investments II, L.P.<sup>[1](https://www.sec.gov/Archives/edgar/data/1672688/000110465921094585/0001104659-21-094585.txt)</sup> His Form 4 filings show continuing service and annual equity compensation: 28,700 stock options awarded on June 8, 2022; 53,100 options on June 14, 2023; and, on June 12, 2024, a direct award of 8,820 common shares plus options on 36,274 shares.<sup>[3](https://www.sec.gov/cgi-bin/own-disp?CIK=0001859522&action=getowner&sortid=ownership-data-ASC)</sup> A directory profile also lists him as a director of Evox Therapeutics, a relationship not confirmed by a primary document in the record used here.<sup>[2](https://theorg.com/org/evox-therapeutics/org-chart/amrit-nagpal)</sup>

## References

1. SEC Section 16 ownership filing, Absci Corp / Nagpal Amrit (CIK 0001859522). https://www.sec.gov/Archives/edgar/data/1672688/000110465921094585/0001104659-21-094585.txt
2. Amrit Nagpal, Director at Evox Therapeutics. The Org. https://theorg.com/org/evox-therapeutics/org-chart/amrit-nagpal
3. SEC EDGAR Section 16 ownership reporting: Nagpal Amrit, Absci Corp Form 4 transactions. https://www.sec.gov/cgi-bin/own-disp?CIK=0001859522&action=getowner&sortid=ownership-data-ASC

---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Venture and growth investors › Life-science venture and company creation › Biotech venture capital partners › Titles A to J*

*Initially written Sep 17, 2026 · Reviewed: Sep 20, 2026 · Edited: Oct 11, 2026 · Last review: Sep 20, 2026*

*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*

License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license